CoChat
Sign Up
Cited by 467Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesPain Management and Opioid Use

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial

Kakko, Johan, Svanborg, Kerstin Dybrandt, Kreek, Mary Jeanne, Heilig, Markus·2003·The Lancet
DOI 10.1016/s0140-6736(03)12600-1
Open this paper in CoChat — free account

Abstract

Background The partial opiate-receptor agonist buprenorphine has been suggested for treatment of heroin dependence, but there are few long-term and placebo-controlled studies of its effectiveness. We aimed to assess the 1-year efficacy of buprenorphine in combination with intensive psychosocial therapy for treatment of heroin dependence.Methods 40 individuals aged older than 20 years, who met DSM-IV criteria for opiate dependence for at least 1 year, but did not fulfil Swedish legal criteria for methadone maintenance treatment were randomly allocated either to daily buprenorphine (fixed dose 16 mg sublingually for 12 months; supervised daily administration for a least 6 months, possible take-home doses thereafter) or a tapered 6 day regimen of buprenorphine, thereafter followed by placebo. All patients participated in cognitive-behavioural group therapy to prevent relapse, received weekly individual counselling sessions, and submitted thrice weekly supervised urine samples for analysis to detect illicit drug use. Our primary endpoint was 1-year retention in treatment and analysis was by intention to treat.Findings 1-year retention in treatment was 75% and 0% in the buprenorphine and placebo groups, respectively (p=0.0001; risk ratio 58.7 [95% CI 7.4-467.4]). Urine screens were about 75% negative for illicit opiates, central stimulants, cannabinoids, and benzodiazepines in the patients remaining in treatment.Interpretation The combination of buprenorphine and intensive psychosocial treatment is safe and highly efficacious, and should be added to the treatment options available for individuals who are dependent on heroin.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(03)12600-1

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 1

  1. Compton, 1994, What dose of buprenorphine reduces opiate use? a double-blind dose-ranging study, NIDA Res Monogr, 153, 138

Cited by

Sorted by citations

Items 301–400 of 467

Related

See all

Metadata

Authors
Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M.
Affiliations
  • Karolinska Institutet (SE)
  • Rockefeller University (US)
Corresponding author
Heilig, Markus
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2003-02
Volume
361
Issue
9358
Pages
662-668
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(03)12600-1
OpenAlex
W2171737529
Cited by
466
References
32
Citations by year
2026: 4 · 2025: 15 · 2024: 13 · 2023: 22 · 2022: 18 · 2021: 27 · 2020: 27 · 2019: 29 · 2018: 26 · 2017: 20 · 2016: 15 · 2015: 25 · 2014: 17 · 2013: 18 · 2012: 19
FWCI
17.61
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • U.S. Public Health Service (P-50-05130, K05 00049)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
buprenorphine, heroin addiction, relapse prevention, treatment retention, social functioning, group cognitive behavioral therapy, psychosocial interventions, urine drug testing, opioid use disorder, sublingual buprenorphine
MeSH terms
Adult, Buprenorphine, Counseling, Female, Heroin Dependence, Humans, Male, Narcotic Antagonists, Psychotherapy, Group, Severity of Illness Index, Sweden, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review